(57) Abstract

5

10

The invention provides a therapeutical composition comprising purified fractions of compounds being or containing a pathogen-inhibiting oligosaccharide sequence for use as a medicament. The present invention especially describes an oligosaccharide-containing substance or receptor binding to diarrheagenic *Escherichia coli* and/or zoonotic *Helicobacter* species, and use thereof in, e.g., pharmaceutical, nutritional and other compositions for prophylaxis and treatment of conditions due to the presence of *Escherichia coli* and/or zoonotic *Helicobacter* species. The invention is also directed to the use of the receptors for diagnostics of *Escherichia coli* and/or zoonotic *Helicobacter* species.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 8 January 2004 (08.01.2004)

PCT

(10) International Publication Number WO 2004/002495 A1

(51) International Patent Classification⁷: A61P 1/04, 1/12

A61K 31/702,

(21) International Application Number:

PCT/FI2003/000528

(22) International Filing Date: 30 June 2003 (30.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20021275 20030564 28 June 2002 (28.06.2002) FI 14 April 2003 (14.04.2003) FI

(71) Applicant (for all designated States except US): BIOTIE THERAPIES OYJ [FI/FI]; Tykistökatu 6, FIN-20520 Turku (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ÅNGSTRÖM, Jonas [SE/SE]; de Geersgatan 12, S-416 57 Göteborg (SE). TENEBERG, Susann [SE/SE]; Postbox 1639, S-430 63 Hindås (SE). SAARINEN, Juhani [FI/FI]; Hiittistenkuja 9 B 20, FIN-00300 Helsinki (FI). SATOMAA, Tero [FI/FI]; Maakaari 6 A 11, FIN-00710 Helsinki (FI). ROCHE, Niamh [SE/SE]; Grevegårdsvägen 146/772, S-421 61 Västra Frölunda (SE). NATUNEN, Jari [FI/FI]; Oolannintie 10 E 18, FIN-01520 Vantaa (FI). MILLER-PODRAZA, Halina [SE/SE]; Lantmilsgatan 20, S-421 37 Västra Frölunda (SE). KARLSSON, Karl-Anders [SE/SE];

Nilssonsberg 37, S-411 43 Göteborg (SE). MILH, Maan, Abul [SE/SE]; Kryddpeppargatan 75, S-424 53 Angered (SE).

- (74) Agent: OY JALO ANT-WUORINEN AB; Iso Roobertinkatu 4-6 A, FIN-00120 Helsinki (FI).
- (81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC COMPOSITIONS FOR USE IN PROPHYLAXIS OR TREATMENT OF DIARRHEAS

(57) Abstract: The invention provides a therapeutical composition comprising purified fractions of compounds being or containing a pathogen-inhibiting oligosaccharide sequence for use as a medicament. The present invention especially describes an oligosaccharide-containing substance or receptor binding to diarrheagenic Escherichia coli and/or zoonotic Helicobacter species, and use thereof in, e.g., pharmaceutical, nutritional and other compositions for prophylaxis and treatment of conditions due to the presence of Escherichia coli and/or zoonotic Helicobacter species. The invention is also directed to the use of the receptors for diagnostics of Escherichia coli and/or zoonotic Helicobacter species.

